Daiichi Sankyo Co Dividend 2025

Mis teeb Daiichi Sankyo Co?

Daiichi Sankyo Co Ltd is a company specialized in the production of medicines. The company was founded in 2005 and was formed from the merger of two Japanese pharmaceutical companies. However, the history of Daiichi Sankyo dates back to 1899 when the Daiichi Group and Sankyo Renkyu merged to form a cooperative. Both companies had been active in the pharmaceutical business since the 1960s and were specialized in the development and production of drugs. Daiichi Sankyo's business model is focused on developing and globally marketing innovative drugs. The company focuses on researching and marketing drugs for the treatment of cancer, cardiovascular diseases, and infectious diseases. Daiichi Sankyo is divided into different divisions. The pharmaceutical division is the company's most important business segment. Here, drugs for various applications are developed and produced, including medications for the therapy of cancer, cardiovascular diseases, and infections. Another division is the medical devices division. Here, medical devices such as catheters and stents for the treatment of cardiovascular diseases, as well as endoscopic devices for the diagnosis and therapy of gastrointestinal diseases, are manufactured. Another important area is the diagnostics division. Here, diagnostic test systems for various applications are developed and manufactured. Some of Daiichi Sankyo's best-known products include the cancer drug Trastuzumab Emtansin and the anticoagulant drug Prasugrel. Daiichi Sankyo is a globally operating company headquartered in Tokyo, Japan. In addition, the company has branches in North, Central, and South America, Europe, Asia, and Oceania. The company places great importance on research and development and participates in numerous collaborations and partnerships with universities and other companies. The goal is to constantly develop new groundbreaking drugs and contribute to the improvement of disease treatment. Overall, Daiichi Sankyo employs approximately 15,000 people worldwide and generates an annual revenue of around 8 billion euros. The company is thus one of the leading companies in the pharmaceutical and medical technology industry and will remain an important player in the global healthcare market in the future. Daiichi Sankyo Co on üks populaarsemaid ettevõtteid saidil Eulerpool.com.